SEC Filing Summary

Jeff Castelli, Chief Development Officer of AMICUS THERAPEUTICS, INC., reported the disposition of 427,089 shares of Common Stock on April 27, 2026, at a price of $14.50 per share. This transaction occurred in connection with the acquisition of the Issuer by BioMarin Pharmaceutical Inc. Additionally, all of Castelli's stock options were cancelled and converted into the right to receive a cash payment based on the difference between $14.50 and the exercise price per share. These options, totaling 82,644, 107,575, 108,266, 125,462, 99,073, and 150,517 shares respectively, were fully vested at the time of the merger. Following these transactions, Castelli holds no shares or options. The filing is Form 4 and is not subject to Section 16.